Edition:
United Kingdom

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

48.40USD
23 May 2018
Change (% chg)

$-1.95 (-3.87%)
Prev Close
$50.35
Open
$50.00
Day's High
$50.55
Day's Low
$47.50
Volume
421,186
Avg. Vol
111,997
52-wk High
$62.70
52-wk Low
$12.20

Select another date:

Wed, May 23 2018

BRIEF-MyoKardia Announces Pricing Of Public Offering Of Common Stock

* MYOKARDIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-MyoKardia Says Offering 3.75 Mln Common Shares

* MYOKARDIA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of Mavacamten

* MYOKARDIA DOSES FIRST PATIENT IN PIONEER OPEN-LABEL EXTENSION STUDY OF MAVACAMTEN FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-MyoKardia Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S

BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten

* HCM TRIAL ARE ANTICIPATED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

BRIEF-Myokardia Files For Potential Mixed Shelf Offering

* MYOKARDIA INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2FCACNv) Further company coverage:

BRIEF-Myokardia Reports Q4 Loss Per Share Of $0.21

* MYOKARDIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491

* MYOKARDIA BEGINS PATIENT DOSING IN PHASE 1B CLINICAL STUDY OF MYK-491 IN DILATED CARDIOMYOPATHY PATIENTS

Select another date: